-The Hindu Business Line The Subramanian panel report on environment regulation should not be accepted in a hurry Environmental governance in India is becoming increasingly contentious. Environmental Quality is declining sharply on indicators such as air, water and forest cover. At the same time, there are calls for regulatory flexibility to enable pursuit of a "development agenda". One of the underlying reasons for the failure of environmental regulation has been the adhocism of...

-The Times of India NEW DELHI: Leading US health groups including AVAC, Oxfam America, amfAR, Health Global Access Project (GAP), TAG (Treatment Action Group)and others have written to Barack Obama urging him to support India in providing "high-Quality, low-cost generic medicines essential for health care around the world". This comes in the wake of the two nations agreeing to enhance engagement on IPR at the latest bilateral talks. Sunday's joint statement after...

-The Indian Express The Annual Status of Education Report (ASER) released last week forced India's policymakers, yet again, to confront the unfortunate realities of our primary education system. In its 10-year history, ASER has challenged the fundamental assumption of elementary education policy: that the expansion of the schooling system would ensure that children learn. Indeed, in the last decade, while the Centre was able to expand the system through the provision...

-The Telegraph New Delhi: A public health expert has questioned the Indian government's commitment to effectively tackling tuberculosis, citing slashed funds, late diagnoses and a failure to curb incorrect or inappropriate prescriptions by many private practitioners. India's plans to eliminate TB as a public health problem by 2050 will remain unachievable without sustained financial support, strong political will and stringent regulation, Mahavir Golechha has said. Golechha is a faculty member with the health...

-The Times of India NEW DELHI: The government may negotiate prices of patented medicines with their manufacturers before allowing pharmaceutical companies to launch them in India. The move, a first of its kind, is also likely to be applied on patented drugs that are already being sold in the country, an official source said. An inter-ministerial committee, evaluating the mechanism to negotiate prices of patented medicines, has recently sought detailed information about...